FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapy

Clinical Nuclear Medicine

Volumn 30, Issue 8, 2005, Pages 564-568

  Joyce, Judith M ^a   Degirmenci, Berna ^a   Jacobs, Samuel ^a   McCook, Barry ^a   Avril, Norbert ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Non Hodgkin lymphoma; PET CT; Radioimmunotherapy; Yttrium 90 ibritumomab tiuxetan; Zevalin

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; INDIUM 111; RITUXIMAB;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOPENIA; DRUG RESPONSE; FEMALE; HUMAN; LYMPH NODE; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; WHOLE BODY SCINTISCANNING;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 22644440954     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000170086.45627.99     Document Type: Article

References (7)

1. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med. 2003;44:2.
2. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med. 1997;38:3.
3. Witzig TE, Gordon LI, Cononillas, et al. Randomized controlled trial of yttrium 90- labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low grade, follicular or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:10.
4. 90Y-labeled anti-cd20 monoclonal antibody. J Nucl Med. 2002;34:2.
5. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002;99:12.
6. Ansell SM, Ristow KM, Habermann TM, et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkins' lymphoma. J Clin Oncol. 2002;20:18.
7. 90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. J Nucl Med Technol. 2003;31:2.